Proven Intelligence Accelerating Next-Generation Therapies.

Executive Summary

The technical framework for producing high-yield AAVrh10 vectors at the 250L single-use bioreactor scale is designed for preclinical cardiovascular programs. The process centers on scalable suspension culture systems, serotype-specific downstream purification, and a comprehensive analytical package to meet requirements for Investigational Medicinal Product Dossier (IMPD) submissions for Advanced Therapy Medicinal Products (ATMPs) in the EMEA region. The objective is to generate sufficient, high-quality vector for large animal IND-enabling toxicology studies within an 18-24 month timeline to first-in-human evaluation.

Scaling Vector Production for Systemic Cardiovascular Delivery

Achieving sufficient vector supply for systemic administration in cardiovascular programs presents a significant manufacturing challenge. The required dose per kilogram for large animal models necessitates production volumes that far exceed what is needed for indications in smaller, compartmentalized organs. Our work focuses on addressing this demand through robust, scalable suspension culture processes in single-use bioreactors.

The transition from small-scale research production to a 250L GxP-compliant run requires a defined process development strategy. This includes:

• Optimization of triple-transfection parameters for suspension HEK293 cell lines.

• Development of a media and feed strategy to maximize cell density and vector productivity.

• Confirmation of process consistency and yield through smaller-scale validation runs (e.g., 10L or 50L) before committing to the 250L batch.

Process and Analytical Considerations

AAVrh10 purification requires a downstream process tailored to the serotype’s specific characteristics to ensure high purity and potency. Our platform utilizes chromatography-based methods to effectively separate full capsids from empty and partially filled particles, a key quality attribute for minimizing immunogenicity and maximizing therapeutic effect.

The analytical characterization of the final vector product is extensive. For a cardiovascular ATMP, the data package must provide a clear line of sight to clinical application. This involves a suite of qualified assays to assess:

• Identity: Serotype-specific ELISA and transgene confirmation.

• Quantity: Vector genome titer by ddPCR.

• Purity: Silver stain and HPLC for protein purity; residual DNA and host cell protein assays.

• Potency: A qualified, gene-of-interest-specific in vitro cell-based assay.

This level of characterization is built upon the collective experience of the field in bringing viral vector therapies forward. The maturation of gene therapy, as noted by leaders like Katherine A. High (PMID: 27983889), depends on this type of manufacturing and analytical rigor to meet regulatory expectations. While early work with vectors like adenovirus demonstrated the potential for durable responses (PMID: 16243818), current standards for AAV require more sophisticated control over product quality attributes.

This integrated approach, combining deep expertise in vector production with robust analytical support, is fundamental to navigating the complexities of AAV manufacturing and ensuring program success.

Advancing Your AAV Program

This focused approach to large-scale AAVrh10 production is one component of our broader capabilities. The Franklin Biolabs team, which includes many experts from the former Penn Vector Core, provides continuity and deep institutional knowledge. Our work since 2019 has resulted in a 100% successful IND rate for our clients, a track record built on rigorous science and manufacturing excellence before the formal launch of the Franklin Biolabs brand in 2024.

To learn more about our full suite of manufacturing services, please see our parent hub page on Large-Scale AAV Manufacturing and Process Development.